Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.76 |
| ▸ | GRM5 | P41594 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15890719 | 0.89 | CYP1A2 (0.81) | CYP1A2CYP2C9GRM5CYP3A4SLC6A3 | |
| SCHEMBL15890666 | 0.88 | CYP1A2 (0.74) | CYP1A2CYP2C9GRM5CYP3A4 | |
| SCHEMBL15890693 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP2C9GRM5CYP3A4SLC6A3 | |
| SCHEMBL15891245 | 0.86 | CYP1A2 (0.62) | CYP1A2CYP2C9GRM5CYP3A4 | |
| SCHEMBL15890664 | 0.85 | CYP1A2 (0.76) | CYP1A2CYP2C9GRM5CYP3A4SLC6A3 | |
| SCHEMBL15890670 | 0.85 | CYP1A2 (0.81) | CYP1A2CYP2C9GRM5CYP3A4SLC6A3 | |
| SCHEMBL15890715 | 0.84 | CYP1A2 (0.81) | CYP1A2CYP2C9GRM5CYP3A4SLC6A3 | |
| SCHEMBL15890678 | 0.80 | CYP1A2 (0.62) | CYP1A2CYP2C9GRM5CYP3A4SLC6A3 | |
| SCHEMBL15890663 | 0.79 | CYP1A2 (0.58) | CYP1A2CYP2C9GRM5CYP3A4SLC6A3 | |
| SCHEMBL15891259 | 0.79 | CYP1A2 (0.77) | CYP1A2CYP2C9GRM5CYP3A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085562-B2 | 6-alkyl-N-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140206707-A1 | 6-ALKYL-N-(PYRIDIN-2-YL)-4-ARYLOXYPICOLINAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206707-A1 | 6-ALKYL-N-(PYRIDIN-2-YL)-4-ARYLOXYPICOLINAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | CYP1A2 3163/4885CYP2C9 3619/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.